Maggie C.U. Cheang

33.9k citations

122 papers · 21.3k indexed · 9 hit papers · h-index 47

Cancer Research top 0.02%
- Breast Cancer Treatment Studies 60
- Cancer Genomics and Diagnostics 14
Oncology top 0.05%
- HER2/EGFR in Cancer Research 51
Pathology and Forensic Medicine top 0.1%
- Breast Lesions and Carcinomas 10
Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 20
Molecular Biology top 0.5%
- Gene expression and cancer classification 11
Genetics
- Estrogen and related hormone effects 20
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 9

Co-authors: Torsten O. Nielsen Charles M. Perou David Voduc Samuel Leung Hagen F. Kennecke Philip S. Bernard Joel S. Parker Stephen Chia
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: JAMA (1 paper)Nature Communications (1 paper)Journal of Clinical Oncology (27 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Maggie C.U. Cheang

118 papers receiving 20.9k citations

Hit Papers

9 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 Science Translational Medicine
2010 Journal of Clinical Oncology
2010 Journal of Clinical Oncology
2010 Clinical Cancer Research
2009 Journal of Clinical Oncology
2009 JNCI Journal of the National Cancer Institute
2008 Clinical Cancer Research
2006 JAMA
2004 Clinical Cancer Research

Peers

Countries citing papers authored by Maggie C.U. Cheang

Since Specialization

Citations

This map shows the geographic impact of Maggie C.U. Cheang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maggie C.U. Cheang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maggie C.U. Cheang more than expected).

Fields of papers citing papers by Maggie C.U. Cheang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maggie C.U. Cheang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maggie C.U. Cheang. The network helps show where Maggie C.U. Cheang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maggie C.U. Cheang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maggie C.U. Cheang Line = papers co-authored together Maggie C.U. Cheang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) Clinical Cancer Research ·Holly Tovey,Orsolya Sipos,Joel S. Parker,Katherine A. Hoadley,Jelmar Quist,Sarah Kernaghan,Lucy Kilburn,Roberto Salgado,Sherene Loi,Richard D. Kennedy,Ioannis Roxanis,Patrycja Gazińska,Sarah E. Pinder,Judith M. Bliss,Charles M. Perou,Syed Haider,Anita Grigoriadis,Andrew Tutt,Maggie C.U. Cheang	2023	3
2	Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna® npj Breast Cancer ·Richard Buus,Zsolt Szíjgyártó,Eugene F. Schuster,Hui Xiao,Ben P. Haynes,Ivana Šestak,Jack Cuzick,Laia Paré,Elia Seguí,Núria Chic,Aleix Prat,Mitch Dowsett,Maggie C.U. Cheang	2021	9
3	Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial The Lancet Oncology ·Ian Smith,J.F.R. Robertson,Lucy Kilburn,Maggie Wilcox,Abigail Evans,Chris Holcombe,Kieran Horgan,Cliona Kirwan,Elizabeth Mallon,Mark Sibbering,Anthony Skene,Raghavan Vidya,Maggie C.U. Cheang,Jane Banerji,James P. Morden,Kally Sidhu,Andrew Dodson,Judith M. Bliss,Mitch Dowsett	2020	147
4	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors Clinical Cancer Research ·Mariana Ferreira Leal,Ben P. Haynes,Eugene F. Schuster,Belinda Yeo,Maria Afentakis,Lila Zabaglo,Vera Martins,Richard Buus,Andrew Dodson,Maggie C.U. Cheang,Ian E. Smith,Lesley‐Ann Martin,Mitch Dowsett	2019	13
5	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients Breast Cancer Research ·(unknown),Qiong Gao,Elena López-Knowles,Maggie C.U. Cheang,James P. Morden,Ricardo Ribas,Kally Sidhu,David M. Evans,Vera Martins,Andrew Dodson,Anthony Skene,Chris Holcombe,Elizabeth Mallon,Abigail Evans,Judith M. Bliss,J.F.R. Robertson,Ian Smith,Lesley‐Ann Martin,Mitch Dowsett	2019	16
6	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics Molecular Cancer Therapeutics ·Jelmar Quist,Hasan Mirza,Maggie C.U. Cheang,Melinda L. Telli,Joyce O’Shaughnessy,Christopher J. Lord,Andrew Tutt,Anita Grigoriadis	2018	20
7	Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC) Oncotarget ·Garrett Barry,Maggie C.U. Cheang,Hector Li Chang,Hagen F. Kennecke	2016	10
8	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy BMC Medicine ·Aleix Prat,Huihui Fan,Aranzazu Fernández-Martínez,Katherine A. Hoadley,Rossella Martinello,María Vidal,Margarita Viladot,Estela Pineda,Ana Arance,Montserrat Muñoz-Mateu,Laia Paré,Maggie C.U. Cheang,Bárbara Adamo,Charles M. Perou	2015	112
9	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Journal of Clinical Oncology ·Lisa A. Carey,Donald A. Berry,Constance Cirrincione,William T. Barry,Brandelyn N. Pitcher,Lyndsay N. Harris,David W. Ollila,Ian E. Krop,N. Lynn Henry,Douglas Weckstein,Carey K. Anders,Baljit Singh,Katherine A. Hoadley,Michael D. Iglesia,Maggie C.U. Cheang,Charles M. Perou,Eric P. Winer,Clifford A. Hudis	2015	263
10	αB-crystallin expression in breast cancer is associated with brain metastasis npj Breast Cancer ·K. David Voduc,Torsten O. Nielsen,Charles M. Perou,J. Chuck Harrell,Cheng Fan,Hagen F. Kennecke,Andy J. Minn,Vincent L. Cryns,Maggie C.U. Cheang	2015	28
11	Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice Clinical Cancer Research ·Jerry Usary,Wei Zhao,David B. Darr,Patrick J. Roberts,Mei Liu,Lorraine Balletta,Olga Karginova,Jamie Jordan,Austin J. Combest,Arlene S. Bridges,Aleix Prat,Maggie C.U. Cheang,Jason I. Herschkowitz,Jeffrey M. Rosen,William C. Zamboni,Norman E. Sharpless,Charles M. Perou	2013	40
12	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer The Oncologist ·Aleix Prat,Bárbara Adamo,Maggie C.U. Cheang,Carey K. Anders,Lisa A. Carey,Charles M. Perou	2013	403
13	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial Clinical Cancer Research ·Maggie C.U. Cheang,K. David Voduc,Dongsheng Tu,Shan Jiang,Samuel Leung,Stephen Chia,Lois E. Shepherd,Mark N. Levine,Kathleen I. Pritchard,Sherri R. Davies,Inge J. Stijleman,Carole Davis,Mark Ebbert,Joel S. Parker,Matthew J. Ellis,Philip S. Bernard,Charles M. Perou,Torsten O. Nielsen	2012	105
14	Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization American Journal Of Pathology ·Atocha Romero,Miguel Martín,Maggie C.U. Cheang,José Antonio López García‐Asenjo,Belén Oliva,Xiaping He,Miguel de la Hoya,José Á. García-Sáenz,Manuel Arroyo Fernández,Eduardo Díaz‐Rubio,Charles M. Perou,Trinidad Caldés Llopis	2011	57
15	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancerbreakdown → Clinical Cancer Research ·Torsten O. Nielsen,Joel S. Parker,Samuel Leung,D. Voduc,Mark Ebbert,Tammi L. Vickery,Sherri R. Davies,Jacqueline Snider,Inge J. Stijleman,Jerry P. Reed,Maggie C.U. Cheang,Elaine R. Mardis,Charles M. Perou,Philip S. Bernard,Matthew J. Ellis	2010	542
16	Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial Journal of Clinical Oncology ·Judith Hugh,John Hanson,Maggie C.U. Cheang,Torsten O. Nielsen,Charles M. Perou,Charles Dumontet,John C. Reed,Maryla Krajewska,Isabelle Treilleux,Matthieu Rupin,E. Magherini,John R. Mackey,Miguel Martín,Charles L. Vogel	2009	407
17	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypesbreakdown → Journal of Clinical Oncology ·Joel S. Parker,Michael E. Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,Christiane Fauron,Xiaping He,Zhiyuan Hu,John F. Quackenbush,Inge J. Stijleman,Juan Palazzo,J. S. Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard	2009	3093
18	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancerbreakdown → JNCI Journal of the National Cancer Institute ·Maggie C.U. Cheang,Stephen Chia,David Voduc,Dongxia Gao,Samuel Leung,Jacqueline Snider,Mark Watson,Sherri R. Davies,Philip S. Bernard,Joel S. Parker,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	2009	1641
19	Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 Cancer Research ·Joyce C. Wu,Cathy Lee,Daniel Yokom,Helen Jiang,Maggie C.U. Cheang,Erika Yorida,Dmitry Turbin,Isabelle M. Berquin,Peter R. Mertens,Thomas Iftner,C. Blake Gilks,Sandra E. Dunn	2006	136
20	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells Oncogene ·Brent W. Sutherland,Jill E. Kucab,Joyce C. Wu,Cathy Lee,Maggie C.U. Cheang,Erika Yorida,Dmitry Turbin,Shoukat Dedhar,Colleen C. Nelson,Michaël Pollak,H. Leighton Grimes,Kathy D. Miller,Sunil Badve,David G. Huntsman,C Blake-Gilks,Min Chen,Catherine J. Pallen,Sandra E. Dunn	2005	249

About Maggie C.U. Cheang

Maggie C.U. Cheang is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 122 papers that have together received 21.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (60 papers), HER2/EGFR in Cancer Research (51 papers), Advanced Breast Cancer Therapies (20 papers), Estrogen and related hormone effects (20 papers), Cancer Genomics and Diagnostics (14 papers), Gene expression and cancer classification (11 papers), Breast Lesions and Carcinomas (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). The work is most often cited by research in Cancer Research (12.4k citations), Oncology (12.6k citations) and Pathology and Forensic Medicine (3.4k citations). Maggie C.U. Cheang has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Torsten O. Nielsen, Charles M. Perou, David Voduc, Samuel Leung, Hagen F. Kennecke, Philip S. Bernard, Joel S. Parker, Stephen Chia, Matthew J. Ellis and Karen A. Gelmon. Their work appears in journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact